These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 20519133)
1. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Yoshida T; Zhang G; Haura EB Biochem Pharmacol; 2010 Sep; 80(5):613-23. PubMed ID: 20519133 [TBL] [Abstract][Full Text] [Related]
2. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Patel JD; Pasche B; Argiris A Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824 [TBL] [Abstract][Full Text] [Related]
3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Jänne PA; Johnson BE Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820 [TBL] [Abstract][Full Text] [Related]
4. Impact of EGFR mutation analysis in non-small cell lung cancer. Yamamoto H; Toyooka S; Mitsudomi T Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859 [TBL] [Abstract][Full Text] [Related]
5. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572 [TBL] [Abstract][Full Text] [Related]
6. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Ray M; Salgia R; Vokes EE Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Agelaki S; Georgoulias V Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567 [TBL] [Abstract][Full Text] [Related]
10. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281 [TBL] [Abstract][Full Text] [Related]
11. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Batus M; Fidler MJ; Bonomi PD Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630 [TBL] [Abstract][Full Text] [Related]
12. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Rossi A; Pasquale R; Esposito C; Normanno N Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519 [TBL] [Abstract][Full Text] [Related]
13. The current status of targeted therapy for non-small cell lung cancer. Francis H; Solomon B Intern Med J; 2010 Sep; 40(9):611-8. PubMed ID: 20002849 [TBL] [Abstract][Full Text] [Related]
14. Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Hammerman PS; Jänne PA; Johnson BE Clin Cancer Res; 2009 Dec; 15(24):7502-7509. PubMed ID: 20008850 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Suda K; Mizuuchi H; Maehara Y; Mitsudomi T Cancer Metastasis Rev; 2012 Dec; 31(3-4):807-14. PubMed ID: 22736441 [TBL] [Abstract][Full Text] [Related]